Paul Rennert, Founder & Principal of SugarCone Biotech LLC, will be attending the joint CRI/AACR event: International Cancer Immunotherapy Conference: Translating Science into Survival 2015. SugarCone Biotech LLC is a consulting firm specializing in biotech strategy and investment.
The conference is in NYC Sept 16-19 and promises to be the key immunotherapy meeting of the fall conference season. Please reach out to connect with Paul at rennertp@sugarconebiotech.com.
Sach’s is a premier international biopartnering event, a highly focused 2-day conference spanning multiple disciplines and therapeutic modalities. Paul Rennert, Founder & Principal of SugarCone Biotech LLC, will be in attendance, to introduce novel programs and companies to interested investors, and conversely, to connect up and coming biotechs and academic spin-outs to the investment community. Please reach out to Paul during the conference using the one-on-one meeting app or via rennertp@sugarconebiotech.com.
We hope to see you there. Here is the conference web site:
http://www.sachsforum.com/15th-annual-biotech-in-europe-forum-for-global-partnering–investment-29-30-september-2015-congress-center-basel.html
The Tumor Microenvironment (TME) series to date is assembled here http://www.sugarconebiotech.com/?s=big+tent containing parts 1-3
I’m happy to point you to the most recent content, posted on Slideshare: http://www.slideshare.net/PaulDRennert/im-vacs-2015-rennert-v2
In this deck I review the challenges of the TME particularly with reference to Pancreatic and Ovarian cancers. A few targets are shown below.
Feedback most welcome.
